Oncology September 26, 2022 NICE recommends MSD’s pembrolizumab to treat melanoma By PBR Staff Writer The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended
RegulationApprovals September 23, 2022 China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer By PBR Staff Writer A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),
RegulationApprovals September 22, 2022 Lilly’s Retevmo receives FDA approval to treat solid tumours By PBR Staff Writer Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene
RegulationApprovals September 21, 2022 Alnylam receives EU marketing authorisation for hATTR amyloidosis therapy By PBR Staff Writer Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization
Drug DiscoveryResearch & Development September 21, 2022 NETRIS Pharma, Orano and CLB partner to develop new radio-conjugates By PBR Staff Writer As part of the partnership deal, the entities will initially plan to conduct a preclinical proof-of-concept efficacy study with the new radio-conjugate targeting Netrin-1, combining Netris’ NP137 with
Research & Development September 20, 2022 FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine By PBR Staff Writer The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen
RegulationApprovals September 19, 2022 Kite’ Yescarta gets CHMP positive opinion to treat large B-cell lymphoma By PBR Staff Writer Yescarta is a chimeric antigen receptor (CAR) T-cell therapy that is indicated to treat diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients whose
Drug DiscoveryResearch & Development September 16, 2022 NeuroBo signs license deal with Dong-A ST to develop two drug candidates By PBR Staff Writer Under the deal terms, NeuroBo will undertake the development, regulatory and commercial works for the two therapies across the world excluding certain Asian-Pacific areas. Dong-A will be responsible
RegulationApprovals September 15, 2022 US FDA approves Mallinckrodt’s Terlivaz for injection to treat hepatorenal syndrome By PBR Staff Writer Terlivaz is claimed to be the first and only FDA-approved product that is indicated for improving kidney function in HRS adult patients with quick kidney function reduction. The
Research & Development September 15, 2022 Coave, IMN partner to develop gene therapy for neurodegenerative disorders By PBR Staff Writer Established in January 2011, IMN is a joint research unit of the University of Bordeaux and the French National Centre of Scientific Research (CNRS). The collaboration will focus